Completed
Carbamazepine and Lorazepam in Outpatient Detoxification
What is being tested
Data Collection
Who is being recruted
Alcoholism+2
+ Mental Disorders
+ Substance-Related Disorders
From 21 to 70 Years
+22 Eligibility Criteria
How is the trial designed
Treatment Study
Phase 4
Interventional
Summary
Principal SponsorNational Institute on Alcohol Abuse and Alcoholism (NIAAA)
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
This project will provide relevant clinical information for primary care practitioners treating alcohol withdrawal syndrome in outpatient settings. This double-blind, placebo- controlled clinical trial will compare the effectiveness of lorazepam (Ativan) and carbamazepine (Tegretol) in alcoholics who meet the criteria for a diagnosis of uncomplicated alcohol withdrawal syndrome. Participants are randomized to five days of treatment with a 1-week posttreatment followup.
Official TitleCarbamazepine and Lorazepam in Outpatient Detoxification
Principal SponsorNational Institute on Alcohol Abuse and Alcoholism (NIAAA)
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.From 21 to 70 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
AlcoholismMental DisordersSubstance-Related DisordersAlcohol-Related DisordersChemically-Induced Disorders
Criteria
6 inclusion criteria required to participate
Subjects must be medically stable.
Must have a clinical withdrawal assessment prior to study.
Meets criteria for alcohol dependence and uncomplicated alcohol withdrawal syndrome.
Ability to provide informed consent, complete self-rating questionnaires, and respond to structured clinician-rated instruments.
Show More Criteria
16 exclusion criteria prevent from participating
Meets criteria for any other substance dependence syndrome other than alcohol dependence or marijuana abuse.
Use of other illicit psychoactive substances (except marijuana) in the last 7 days.
Use of pharmaceutical agents within the last 14 days that are known to lower the seizure threshold, augment or decrease the alcohol withdrawal syndrome.
History of status epilepticus or two or more seizures occurring within 24- hour period during a previous alcohol withdrawal or other forms of epilepsy.
Show More Criteria
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Suspended
Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina
Charleston, United StatesOpen Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina in Google MapsCompletedOne Study Center